A Phase I Study of IMMU-130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Colorectal Cancer.
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2015
At a glance
- Drugs Labetuzumab govitecan (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Immunomedics
- 14 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 02 Jun 2014 Results in 21 patients published in Immunomedics media release.
- 06 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History